Mycoplasma haemofelis
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Mycoplasma haemofelis is a wall-less bacterium (Mollicutes) that parasitizes the surface of feline erythrocytes, causing feline infectious anemia (FIA). It is taxonomically distinct from its historical classification as Haemobartonella felis.
- The primary transmission routes are direct blood transfer (fighting, transfusions, iatrogenic means), with vector-borne transmission (fleas, ticks) being less definitively established and potentially confounded by detection of host blood.
- Pathogenesis involves erythrocyte adherence, leading to structural changes and extravascular hemolysis mediated by macrophages, resulting in regenerative, macrocytic anemia. Co-infections with FIV/FeLV and endothelial glycocalyx injury can exacerbate disease.
- Diagnosis is definitively established via PCR (conventional or real-time) targeting the 16S rRNA gene, offering superior sensitivity and specificity over blood smear microscopy.
- Treatment involves doxycycline as the first-line antimicrobial for 14-21 days, with fluoroquinolones as alternatives. Supportive care, including blood transfusions for PCV < 12-15%, is crucial in severe cases.
- Prevention focuses on minimizing exposure to risk factors such as outdoor access and ectoparasites, and screening blood donors for hemoplasmas. No vaccine is currently available.
Introduction
Mycoplasma haemofelis is a hemotropic bacterial pathogen (hemoplasma) that parasitizes the surface of feline erythrocytes and constitutes the primary etiologic agent of feline infectious anemia (FIA) [<a href="#ref-1">1</a>]. This organism is a member of the class Mollicutes, characterized by the absence of a cell wall and a reduced genome that limits biosynthetic capacity and necessitates a parasitic lifestyle [<a href="#ref-1">1</a>]. Infection with M. haemofelis can result in a spectrum of clinical outcomes ranging from subclinical carrier states to severe, life-threatening hemolytic anemia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. The global distribution of this pathogen and its impact on both domestic and wild felid populations have made it a subject of intensive molecular epidemiological investigation [<a href="#ref-4">4</a>, <a href="#ref-5">5</a>, <a href="#ref-6">6</a>].
Taxonomy and Classification
Mycoplasma haemofelis belongs to the hemotropic mycoplasma group (hemoplasmas), which are wall-less bacteria that adhere to the surface of erythrocytes [<a href="#ref-1">1</a>]. Historically classified as Haemobartonella felis, the organism was reclassified into the genus Mycoplasma based on 16S rRNA gene sequencing and phylogenetic analyses [<a href="#ref-1">1</a>]. The hemotropic mycoplasmas infecting felids include M. haemofelis, "Candidatus Mycoplasma haemominutum", and "Candidatus Mycoplasma turicensis" [<a href="#ref-1">1</a>, <a href="#ref-7">7</a>]. These species differ in pathogenicity, with M. haemofelis generally considered the most virulent [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. The "Candidatus" designation for M. haemominutum and M. turicensis reflects the inability to culture these organisms axenically, a limitation that also applies to M. haemofelis despite its greater virulence [<a href="#ref-1">1</a>].
Morphology and Biophysical Characteristics
Mycoplasma haemofelis cells are pleomorphic, coccoid to rod-shaped organisms that lack a cell wall and are bounded only by a plasma membrane [<a href="#ref-1">1</a>]. The absence of a cell wall renders the organism intrinsically resistant to beta-lactam antimicrobials and necessitates reliance on alternative molecular targets for therapeutic intervention [<a href="#ref-1">1</a>]. The organism measures approximately 0.3 to 0.8 micrometers in diameter and adheres to the erythrocyte surface via specialized adhesins, though the precise molecular identity of these adhesins remains incompletely characterized [<a href="#ref-1">1</a>]. The reduced genome of hemotropic mycoplasmas, typically less than 1 megabase, encodes a limited repertoire of metabolic enzymes, making the organism dependent on the host cell for nutrients such as cholesterol and nucleotides [<a href="#ref-1">1</a>].
Epidemiology and Global Distribution
Mycoplasma haemofelis infection has been documented in domestic cat populations across all inhabited continents, with prevalence rates varying widely by geographic region, diagnostic method, and study population [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-8">8</a>, <a href="#ref-9">9</a>, <a href="#ref-10">10</a>, <a href="#ref-11">11</a>, <a href="#ref-12">12</a>, <a href="#ref-13">13</a>, <a href="#ref-14">14</a>, <a href="#ref-15">15</a>, <a href="#ref-16">16</a>, <a href="#ref-17">17</a>, <a href="#ref-18">18</a>, <a href="#ref-19">19</a>, <a href="#ref-20">20</a>]. A global systematic review and meta-analysis reported pooled prevalence estimates for hemoplasma infections in domestic cats, with M. haemofelis consistently detected at lower frequencies than "Ca. M. haemominutum" in most regions [<a href="#ref-4">4</a>]. In Asia, molecular surveys have identified M. haemofelis in cats from Thailand [<a href="#ref-10">10</a>, <a href="#ref-14">14</a>, <a href="#ref-21">21</a>, <a href="#ref-22">22</a>], Taiwan [<a href="#ref-9">9</a>], Vietnam [<a href="#ref-3">3</a>], Indonesia [<a href="#ref-23">23</a>], and China [<a href="#ref-15">15</a>]. Studies in Iran have reported prevalence rates ranging from 2.5% to over 10% depending on the population sampled [<a href="#ref-2">2</a>, <a href="#ref-8">8</a>, <a href="#ref-16">16</a>]. In Europe, prevalence in owned cats varies but is generally lower than in stray or shelter populations [<a href="#ref-6">6</a>, <a href="#ref-20">20</a>, <a href="#ref-24">24</a>, <a href="#ref-25">25</a>]. In the Americas, molecular detection has been reported in Brazil [<a href="#ref-5">5</a>, <a href="#ref-11">11</a>, <a href="#ref-12">12</a>, <a href="#ref-18">18</a>, <a href="#ref-19">19</a>, <a href="#ref-26">26</a>], Paraguay [<a href="#ref-13">13</a>], and the United States [<a href="#ref-27">27</a>, <a href="#ref-28">28</a>]. In Africa, surveys have identified hemoplasma DNA in cat populations from sub-Saharan regions [<a href="#ref-29">29</a>]. In the Middle East, studies in Iraq [<a href="#ref-30">30</a>], Turkey [<a href="#ref-31">31</a>, <a href="#ref-32">32</a>, <a href="#ref-33">33</a>], and Egypt [<a href="#ref-7">7</a>] have contributed to the growing body of prevalence data.
Risk Factors
Several risk factors have been consistently associated with M. haemofelis infection. Male sex, non-pedigree breed, outdoor access, and older age have been identified as significant predictors in multiple studies [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-12">12</a>, <a href="#ref-13">13</a>, <a href="#ref-16">16</a>, <a href="#ref-20">20</a>, <a href="#ref-24">24</a>]. Co-infection with feline retroviruses, particularly feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), is a well-established risk factor, likely due to retrovirus-induced immunosuppression that facilitates hemoplasma proliferation [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>, <a href="#ref-34">34</a>]. Ectoparasite infestation, especially with the cat flea Ctenocephalides felis, is strongly associated with infection, although the role of fleas as biological vectors versus mechanical vectors remains under investigation [<a href="#ref-17">17</a>, <a href="#ref-23">23</a>, <a href="#ref-27">27</a>, <a href="#ref-29">29</a>]. A systematic review and meta-analysis of hemoplasma in C. felis concluded that many previous reports of hemoplasma DNA in fleas may represent detection of host blood-derived DNA rather than true vector infection, complicating the understanding of transmission dynamics [<a href="#ref-27">27</a>].
Transmission
The primary mode of M. haemofelis transmission is believed to be through direct blood transfer, which can occur via fighting (bite wounds), blood transfusion from an infected donor, or iatrogenic means such as contaminated needles [<a href="#ref-1">1</a>, <a href="#ref-24">24</a>]. Vector-borne transmission has been proposed, with the cat flea C. felis considered a potential vector [<a href="#ref-17">17</a>, <a href="#ref-23">23</a>, <a href="#ref-27">27</a>]. However, the role of fleas remains controversial. A systematic review and meta-analysis found that many studies reporting hemoplasma DNA in fleas may have detected residual host blood rather than true infection of the flea, and experimental transmission studies have not consistently demonstrated flea-borne transmission [<a href="#ref-27">27</a>]. Tick-borne transmission has also been suggested, and hemoplasma DNA has been detected in tick species feeding on cats, but definitive vector competence studies are lacking [<a href="#ref-15">15</a>, <a href="#ref-17">17</a>]. Transmission via blood transfusion is a well-documented iatrogenic route, and screening of blood donor cats for hemoplasmas is recommended to prevent transfusion-associated infection [<a href="#ref-24">24</a>].
Pathogenesis and Host-Pathogen Interactions
The pathogenesis of M. haemofelis infection is primarily driven by the organism's adherence to the erythrocyte membrane, which induces structural and antigenic changes that trigger extravascular hemolysis [<a href="#ref-1">1</a>]. The binding of M. haemofelis to the erythrocyte surface is mediated by adhesin proteins, though the specific adhesin-receptor interactions have not been fully elucidated at the molecular level [<a href="#ref-1">1</a>]. Adherence leads to increased membrane rigidity, reduced deformability, and exposure of cryptic antigens, which in turn promotes recognition and phagocytosis by macrophages in the spleen, liver, and bone marrow [<a href="#ref-1">1</a>]. The resulting anemia is typically regenerative and macrocytic, with a marked reticulocytosis observed in the acute phase [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>].
The severity of anemia is influenced by the bacterial load, the host immune response, and the presence of co-infections [<a href="#ref-2">2</a>, <a href="#ref-19">19</a>, <a href="#ref-28">28</a>, <a href="#ref-33">33</a>]. In some cases, infection can trigger hemophagocytic syndrome, a severe inflammatory condition characterized by uncontrolled activation of macrophages and histiocytes that phagocytose erythrocytes, leukocytes, and platelets [<a href="#ref-28">28</a>]. This syndrome can exacerbate cytopenias and complicate clinical management [<a href="#ref-28">28</a>]. Biomarkers of endothelial glycocalyx injury, such as syndecan-1 and hyaluronan, have been shown to be elevated in cats with hemotropic mycoplasmosis, indicating that vascular endothelial damage may contribute to the pathophysiology of the disease [<a href="#ref-33">33</a>].
Clinical Signs and Clinicopathologic Abnormalities
The clinical presentation of M. haemofelis infection ranges from subclinical to peracute hemolytic crisis [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. In the acute phase, cats typically present with lethargy, pale mucous membranes, tachycardia, tachypnea, and anorexia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. Icterus may be present due to extravascular hemolysis and subsequent bilirubin accumulation [<a href="#ref-1">1</a>]. Fever is variable but can occur during the acute hemolytic episode [<a href="#ref-1">1</a>]. In peracute cases, sudden collapse and death may occur due to severe hypoxemia and hemolytic shock [<a href="#ref-1">1</a>].
Clinicopathologic abnormalities are dominated by a regenerative, macrocytic, hypochromic anemia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-8">8</a>]. The packed cell volume (PCV) can fall below 10% in severe cases [<a href="#ref-1">1</a>]. The reticulocyte count is elevated, reflecting a bone marrow response to the anemia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. Serum biochemistry may reveal hyperbilirubinemia and elevated liver enzyme activities secondary to hepatic hypoxia and hemolysis [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. Inflammatory leukograms, including neutrophilia and monocytosis, are common [<a href="#ref-2">2</a>]. Thrombocytopenia has been reported in some cases, though it is not a consistent finding [<a href="#ref-1">1</a>]. Co-infection with FeLV or FIV can exacerbate the severity of anemia and delay recovery [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>, <a href="#ref-34">34</a>].
Molecular Detection and Diagnostic Approaches
Definitive diagnosis of M. haemofelis infection relies on molecular detection of the organism's DNA, most commonly via conventional or real-time polymerase chain reaction (PCR) assays targeting the 16S rRNA gene [<a href="#ref-1">1</a>, <a href="#ref-22">22</a>, <a href="#ref-30">30</a>, <a href="#ref-31">31</a>, <a href="#ref-35">35</a>]. PCR-based methods offer superior sensitivity and specificity compared to cytologic examination of blood smears, which suffers from low sensitivity and the potential for misidentification of stain precipitate or Howell-Jolly bodies as hemoplasmas [<a href="#ref-1">1</a>]. Quantitative real-time PCR (qPCR) assays allow for the determination of bacterial load, which can be correlated with disease severity and used to monitor response to therapy [<a href="#ref-1">1</a>].
Several PCR formats have been developed for the detection and differentiation of feline hemoplasma species. Conventional PCR assays using species-specific primers targeting the 16S rRNA gene can distinguish M. haemofelis from "Ca. M. haemominutum" and "Ca. M. turicensis" based on amplicon size or subsequent sequencing [<a href="#ref-22">22</a>, <a href="#ref-31">31</a>, <a href="#ref-35">35</a>]. Triplex PCR assays that simultaneously detect all three feline hemoplasma species in a single reaction have been described and validated [<a href="#ref-31">31</a>]. These assays typically incorporate three sets of primers, each producing an amplicon of a distinct size that can be resolved by gel electrophoresis [<a href="#ref-31">31</a>]. Real-time PCR assays using species-specific probes provide quantitative data and are considered the gold standard for diagnosis and monitoring [<a href="#ref-1">1</a>].
The choice of genetic target is critical for assay performance. The 16S rRNA gene is the most commonly used target due to its presence in multiple copies per genome, which enhances analytical sensitivity, and its conserved and variable regions that allow for both broad-range and species-specific detection [<a href="#ref-1">1</a>, <a href="#ref-22">22</a>, <a href="#ref-31">31</a>]. However, the high degree of sequence similarity among hemoplasma 16S rRNA genes necessitates careful primer design to avoid cross-reactivity [<a href="#ref-21">21</a>, <a href="#ref-22">22</a>]. The use of alternative genetic markers, such as the RNase P RNA gene (rnpB) or the heat shock protein 70 gene (dnaK), has been explored to improve phylogenetic resolution and species discrimination [<a href="#ref-21">21</a>].
Diagnostic Workflow
The following Mermaid diagram illustrates a typical diagnostic workflow for a cat presenting with clinical signs suggestive of hemotropic mycoplasmosis.
flowchart TD
A["Cat presenting with lethargy, pallor, anorexia"] --> B{"PCV < 20%?"}
B -->|"Yes"| C["Blood smear examination"]
B -->|"No"| D["Monitor; consider PCR if clinical suspicion high"]
C --> E{"Organisms visible on smear?"}
E -->|"Yes"| F["Presumptive hemoplasma infection"]
E -->|"No"| G["Perform species-specific PCR"]
F --> H["Confirm with species-specific PCR"]
G --> I{"PCR positive?"}
I -->|"Yes"| J["Identify species via sequencing or triplex PCR"]
I -->|"No"| K["Consider alternative diagnoses"]
J --> L["Assess co-infections: FeLV, FIV"]
L --> M["Initiate appropriate antimicrobial therapy"]
M --> N["Monitor PCV and clinical response"]Treatment and Antimicrobial Susceptibility
The mainstay of therapy for M. haemofelis infection is the administration of antimicrobials effective against cell-wall-deficient bacteria [<a href="#ref-1">1</a>]. Doxycycline is the first-line agent of choice, typically administered orally at 5 to 10 mg/kg every 12 to 24 hours for a minimum of 14 to 21 days [<a href="#ref-1">1</a>]. Doxycycline inhibits protein synthesis by binding to the 30S ribosomal subunit, and its lipophilic nature facilitates intracellular penetration [<a href="#ref-1">1</a>]. Fluoroquinolones, such as enrofloxacin or marbofloxacin, are considered second-line agents and may be used in cases of doxycycline intolerance or treatment failure [<a href="#ref-1">1</a>]. These agents inhibit DNA gyrase and topoisomerase IV, leading to bacterial DNA replication arrest [<a href="#ref-1">1</a>]. Macrolides, including azithromycin, have also been used, though clinical efficacy data are more limited [<a href="#ref-1">1</a>].
Supportive care is critical in severely anemic cats. Blood transfusion may be necessary when the PCV falls below 12% to 15% or when clinical signs of hypoxemia are severe [<a href="#ref-1">1</a>]. Corticosteroids, such as prednisolone, are sometimes used to suppress immune-mediated erythrocyte destruction, but their use is controversial and should be reserved for cases with documented immune-mediated hemolytic anemia (IMHA) secondary to infection [<a href="#ref-1">1</a>]. The prognosis for cats that receive prompt and appropriate therapy is generally good, though relapses can occur, particularly in cats that remain infected or are co-infected with retroviruses [<a href="#ref-1">1</a>].
Prevention and Control
Prevention of M. haemofelis infection centers on reducing exposure to risk factors. Keeping cats indoors reduces the likelihood of fighting and ectoparasite exposure [<a href="#ref-1">1</a>]. Regular use of veterinary-approved ectoparasiticides to control flea and tick infestations is recommended [<a href="#ref-1">1</a>, <a href="#ref-17">17</a>, <a href="#ref-23">23</a>]. Screening of potential feline blood donors for hemoplasma infection using PCR is essential to prevent transfusion-transmitted infection [<a href="#ref-24">24</a>]. There is no commercially available vaccine for M. haemofelis [<a href="#ref-1">1</a>].
Public Health Considerations
Mycoplasma haemofelis is not considered a zoonotic pathogen. The organism is highly host-adapted to felids and has not been documented to cause infection in humans [<a href="#ref-1">1</a>]. This host restriction is consistent with the general pattern observed for hemotropic mycoplasmas, which typically exhibit narrow host ranges [<a href="#ref-1">1</a>].
Frequently Asked Questions
What is Mycoplasma haemofelis?
Mycoplasma haemofelis is a hemotropic bacterial pathogen that infects cats and attaches to the surface of red blood cells, causing hemolytic anemia [<a href="#ref-1">1</a>].
How is Mycoplasma haemofelis transmitted?
Transmission occurs primarily through direct blood transfer via bite wounds, blood transfusion, or contaminated instruments. The role of fleas as vectors is debated, with some evidence suggesting that flea-borne transmission may be less significant than previously thought [<a href="#ref-1">1</a>, <a href="#ref-23">23</a>, <a href="#ref-27">27</a>].
What are the clinical signs of Mycoplasma haemofelis infection?
Clinical signs include lethargy, pale mucous membranes, anorexia, tachycardia, tachypnea, and icterus, all resulting from hemolytic anemia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>, <a href="#ref-3">3</a>].
How is Mycoplasma haemofelis diagnosed?
Diagnosis is confirmed by PCR testing of blood, which detects the organism's DNA with high sensitivity and specificity. Blood smear examination can be suggestive but is less reliable [<a href="#ref-1">1</a>, <a href="#ref-22">22</a>, <a href="#ref-30">30</a>, <a href="#ref-31">31</a>, <a href="#ref-35">35</a>].
What is the treatment for Mycoplasma haemofelis?
The recommended treatment is doxycycline administered orally for at least 14 to 21 days. Supportive care, including blood transfusion in severe cases, may be necessary [<a href="#ref-1">1</a>].
Can Mycoplasma haemofelis infect humans?
No, M. haemofelis is not zoonotic and does not infect humans [<a href="#ref-1">1</a>].
Is there a vaccine for Mycoplasma haemofelis?
No vaccine is currently available for M. haemofelis [<a href="#ref-1">1</a>].